Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jack W Singer

Showing results (11-20 of 42) with videos related to

Pageof 5
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|November 30, 2012
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patientsEmanuela Salvatorelli, Pierantonio Menna, Odalys Gonzalez Paz, et al.
Journal of Medicinal Chemistry|December 28, 2002
Synthesis and in vivo antitumor activity of poly(l-glutamic acid) conjugates of 20S-camptothecinRama Bhatt, Peter de Vries, John Tulinsky, et al.
International Journal of General Medicine|March 16, 2011
Procoagulant inhibitory properties of paclitaxel poliglumexJohn Nemunaitis, Neil Senzer, Barry Cooper, et al.
Experimental Cell Research|May 16, 2016
Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal gowth factor receptor mutation-positive non-small cell lung CancerNobuaki Ochi, Hideko Isozaki, Masami Takeyama, et al.
Clinical Therapeutics|February 10, 2016
The Cost-effectiveness of Pixantrone for Third/Fourth-line Treatment of Aggressive Non-Hodgkin's LymphomaNoemi Muszbek, Ananth Kadambi, Tereza Lanitis, et al.
Leukemia Research|February 21, 2006
Effect of lysophosphatidic acid acyltransferase-beta inhibition in acute leukemiaMichael G Douvas, Karen N Hogan, YanShan Ji, et al.
Molecular Cancer|May 14, 2004
Phospholipase C delta-4 overexpression upregulates ErbB1/2 expression, Erk signaling pathway, and proliferation in MCF-7 cellsDavid W Leung, Chris Tompkins, Jim Brewer, et al.
Cancer Chemotherapy and Pharmacology|August 23, 2006
In vitro and in vivo metabolism of paclitaxel poliglumex: identification of metabolites and active proteasesScott A Shaffer, Cassie Baker-Lee, Jacob Kennedy, et al.
Bioorganic & Medicinal Chemistry Letters|April 15, 2004
Synthesis, SAR, and antitumor properties of diamino-C,N-diarylpyrimidine positional isomers: inhibitors of lysophosphatidic acid acyltransferase-betaBaoqing Gong, Feng Hong, Cory Kohm, et al.
Leukemia & Lymphoma|March 29, 2011
Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphomaPeter Borchmann, Raoul Herbrecht, Martin Wilhelm, et al.
Pageof 5

Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
The Journal of Pharmacology and Experimental Therapeutics|November 30, 2012
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patientsEmanuela Salvatorelli, Pierantonio Menna, Odalys Gonzalez Paz, et al.
Journal of Medicinal Chemistry|December 28, 2002
Synthesis and in vivo antitumor activity of poly(l-glutamic acid) conjugates of 20S-camptothecinRama Bhatt, Peter de Vries, John Tulinsky, et al.
International Journal of General Medicine|March 16, 2011
Procoagulant inhibitory properties of paclitaxel poliglumexJohn Nemunaitis, Neil Senzer, Barry Cooper, et al.
Experimental Cell Research|May 16, 2016
Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal gowth factor receptor mutation-positive non-small cell lung CancerNobuaki Ochi, Hideko Isozaki, Masami Takeyama, et al.
Clinical Therapeutics|February 10, 2016
The Cost-effectiveness of Pixantrone for Third/Fourth-line Treatment of Aggressive Non-Hodgkin's LymphomaNoemi Muszbek, Ananth Kadambi, Tereza Lanitis, et al.
Leukemia Research|February 21, 2006
Effect of lysophosphatidic acid acyltransferase-beta inhibition in acute leukemiaMichael G Douvas, Karen N Hogan, YanShan Ji, et al.
Molecular Cancer|May 14, 2004
Phospholipase C delta-4 overexpression upregulates ErbB1/2 expression, Erk signaling pathway, and proliferation in MCF-7 cellsDavid W Leung, Chris Tompkins, Jim Brewer, et al.
Cancer Chemotherapy and Pharmacology|August 23, 2006
In vitro and in vivo metabolism of paclitaxel poliglumex: identification of metabolites and active proteasesScott A Shaffer, Cassie Baker-Lee, Jacob Kennedy, et al.
Bioorganic & Medicinal Chemistry Letters|April 15, 2004
Synthesis, SAR, and antitumor properties of diamino-C,N-diarylpyrimidine positional isomers: inhibitors of lysophosphatidic acid acyltransferase-betaBaoqing Gong, Feng Hong, Cory Kohm, et al.
Leukemia & Lymphoma|March 29, 2011
Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphomaPeter Borchmann, Raoul Herbrecht, Martin Wilhelm, et al.
Pageof 5